TSRO : Summary for TESARO, Inc. - Yahoo Finance

U.S. Markets open in 2 hrs 23 mins

Tesaro, Inc. (TSRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
156.56-3.44 (-2.15%)
At close: 4:00PM EDT

167.89 11.16 (7.12%)
Pre-Market: 7:06AM EDT

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close160.00
Bid166.00 x 100
Ask167.88 x 200
Day's Range153.61 - 159.51
52 Week Range36.68 - 192.94
Avg. Volume1,003,540
Market Cap8.4B
PE Ratio (TTM)-19.25
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia3 hours ago

    Tesaro Secures FDA Nod for Ovarian Cancer Drug

    Zejula's early approval means a tough fight for AstraZeneca's Lynparza, which has been one of the bestsellers for ovarian cancer

  • American City Business Journals10 hours ago

    Tesaro wins FDA approval for potential blockbuster cancer drug

    The FDA has approved an ovarian cancer drug developed by Waltham-based Tesaro that some analysts believe could surpass $2 billion in peak sales. Shares of Tesaro (TSRO) were up 6 percent in after-hours trading as of 8 p.m. after the company announced the approval of niraparib, a once-daily pill that will be sold under the brand name Zejula. It covers patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer who have responded — either partially or completely — to chemotherapy.

  • After-hours buzz: RHT, DRI, TSRO & more
    CNBC13 hours ago

    After-hours buzz: RHT, DRI, TSRO & more

    These are the stocks posting the largest moves after the bell.